CVA Family Office’s Haemonetics HAE Stock Holding History

CVA Family Office’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.17K	Buy	69 +13	+23%	+$835	﹤0.01%	1262
2026 Q1	$3.16K	Buy	+56	New	+$3.65K	﹤0.01%	1393

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CVA Family Office's HAE Position: Q2 2026 in Review

CVA Family Office increased its Haemonetics (HAE) stake by 23% in Q2 2026, buying an estimated $835 and bringing the position to 69 shares worth $5.17K. The position accounts for ﹤0.01% of the portfolio, ranked #1262.

CVA Family Office first reported a position in HAE in Q1 2026 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

CVA Family Office held 69 shares of Haemonetics worth $5.17K as of Q2 2026.
CVA Family Office bought 13 Haemonetics shares in Q2 2026, an estimated $835.
Haemonetics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1262 holding.
CVA Family Office first reported a position in Haemonetics in Q1 2026 and has held it in 2 quarters since.
329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.